Where Editas Medicine Stands With Analysts

Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sent…

Analyst Ratings For Penumbra

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Penumbra (NYSE:PEN) in the last three months. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past…